Keystone Financial Group Inc. Acquires 2,889 Shares of Danaher Corporation $DHR

Keystone Financial Group Inc. acquired a new stake in Danaher Corporation (NYSE:DHR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,889 shares of the conglomerate’s stock, valued at approximately $640,000.

A number of other large investors have also recently made changes to their positions in DHR. BlackRock Inc. bought a new stake in shares of Danaher during the second quarter worth about $10,492,520,000. Wellington Management Group LLP raised its holdings in shares of Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Danaher in the 2nd quarter worth about $1,456,317,000. Generation Investment Management LLP bought a new position in Danaher in the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE bought a new position in Danaher in the 2nd quarter valued at about $993,846,000. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Royal Bank Of Canada increased their price objective on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Morgan Stanley raised their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday. Wells Fargo & Company dropped their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Finally, Stifel Nicolaus cut their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $235.41.

Danaher Stock Performance

Shares of DHR stock opened at $223.30 on Wednesday. The firm has a 50-day moving average of $212.41 and a 200-day moving average of $195.13. The company has a market cap of $156.98 billion, a P/E ratio of 39.66, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the firm earned $0.77 earnings per share. The firm’s revenue was up 5.5% on a year-over-year basis. Equities research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.